Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer.

Kasey R CargillC Allison StewartElizabeth M ParkKavya RamkumarCarl M GayRobert J CardnellQi WangLixia DiaoLi ShenYou-Hong FanWai Kin ChanPhilip L LorenziTrudy G OliverJing WangLauren Averett Byers

Published in: Cancer & metabolism (2021)

Our study highlights an in-depth characterization of SCLC metabolic programming and presents glycolysis as a targetable mechanism downstream of MYC that could offer therapeutic benefit in a subset of SCLC patients.

Keyphrases

small cell lung cancer
end stage renal disease
chronic kidney disease
ejection fraction
transcription factor
newly diagnosed
peritoneal dialysis
cancer therapy
drug delivery
patient reported